Project Grant R21AI185484
Award Date
7/17/25
Completion Date
6/30/27
Dollars Obligated
$236K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $721,194 to Florida State University to conduct research on the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: (1) investigate the structural and functional roles of the FtsQ-FtsZ protein interaction; (2) characterize the structure,...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award of $2,248,740.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research by Michigan State University to develop new nitro-containing compounds to treat mycobacterial infections, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The key products and services to be delivered include: Optimizing a series of novel nitrofuran compounds, such as the parent...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The $820,246 award to the Albert Einstein College of Medicine will be used to investigate the roles of these secreted proteins in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility test (termed TRE-DST) for tuberculosis (TB). The TRE-DST system utilizes novel fluorescent trehalose probes to detect live Mycobacterium tuberculosis and determine drug resistance, addressing limitations of current diagnostic methods. Key...
This Project Grant award of $265,650 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel medicinal chemistry strategies to overcome multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). The research aims to establish the structure-activity relationship and mechanism of action of modified rifabutin analogs that demonstrate enhanced potency against...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $423,500.00 to the Regents of the University of Minnesota to conduct research on phenylalanine (Phe) biosynthesis as a potential drug target for treating tuberculosis (TB). The research aims to determine the extent to which Mycobacterium tuberculosis (MTB) requires Phe synthesis during infection and how inhibiting Phe...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...